An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: Evaluate safety and efficacy of mixed amphetamine salts extended release (MAS XR) in adults with attention-deficit/hyperactivity disorder (ADHD). Methods: 10-week interim analysis of the Quality of life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) trial, an ongoing, 30-week, open-label, multicenter investigation of once-daily MAS XR (10–60 mg/day) in adults (≥18 years of age) with ADHD in community practice settings. Findings: With up to 10 weeks of open-label MAS XR 10 to 60 mg/day (final visit mean dose: 37.2 mg/day), 725 adults exhibited rapid, sustained improvement in ADHD symptoms. At end point, significant decreases from baseline were seen in ADHD Rating Scale IV total scores (-19.8±11.6; P<.0001), hyperactivity/impulsivity subscak (-8.1±6.1; P<.0001), and inattentive subscale (-11.6±6.7; P<.0001). Most subjects (74.4%) were rated as very much/much improved. Based on the 36- item Short Form Health Survey (version 2), significant improvements in quality of life were seen in the domains of general health, physical and mental health, vitality, and social, emotional and physical role functioning (P<.0001). Few subjects (6.9%) withdrew due to adverse events; the most common MAS XR-related adverse events were decreased appetite and dry mouth (19.2% each), insomnia (17.8%), and headache (16.8%). Conclusion: In adults with ADHD, MAS XR treatment is generally safe and demonstrates significant improvement in ADHD symptoms and related quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biederman, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.816 · Cited by 1,498
Assessment of the SF-36 version 2 in the United Kingdom.
Jenkinson, C., Stewart-Brown, S., Petersen, S., & Paice, C. (1999) · Journal of Epidemiology and Community Health · doi:10.1136/jech.53.1.46 · Cited by 565
BIEDERMAN, J., FARAONE, S., MILBERGER, S., CURTIS, S., CHEN, L., MARRS, A., OUELLETTE, C., MOORE, P., & SPENCER, T. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199603000-00016 · Cited by 510
The epidemiology of attention‐deficit/hyperactivity disorder (ADHD): A public health view
Rowland, A. S., Lesesne, C. A., & Abramowitz, A. J. (2002) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.10036 · Cited by 495
Spencer, T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180020004 · Cited by 402
Gender effects on Attention-Deficit/Hyperactivity disorder in adults, revisited
Biederman, J., Faraone, S. V., Monuteaux, M. C., Bober, M., & Cadogen, E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.12.003 · Cited by 385
Spencer, T., Biederman, J., Wilens, T., Faraone, S., Prince, J., Gerard, K., Doyle, R., Parekh, A., Kagan, J., & Bearman, S. K. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.8.775 · Cited by 250
WILENS, T., PELHAM, W., STEIN, M., CONNERS, C. K., ABIKOFF, H., ATKINS, M., AUGUST, G., GREENHILL, L., MCBURNETT, K., PALUMBO, D., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000046814.95464.7d · Cited by 148
Cited by
Amphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 617
Attention-deficit/hyperactivity disorder
Faraone, S. V., Bellgrove, M. A., Brikell, I., Cortese, S., Hartman, C. A., Hollis, C., Newcorn, J. H., Philipsen, A., Polanczyk, G. V., Rubia, K., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00495-0 · Cited by 355
Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults
Castells, X., Blanco-Silvente, L., & Cunill, R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007813.pub3 · Cited by 209
Coghill, D. (2010) · CNS Drugs · doi:10.2165/11537450-000000000-00000 · Cited by 103
Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults
Castells, X., Ramos-Quiroga, J. A., Bosch, R., Nogueira, M., & Casas, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007813.pub2 · Cited by 80
Metadata
- Authors
- Goodman, D. W., Ginsberg, L., Weisler, R. H., Cutler, A. J., & Hodgkins, P.
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2005-12
- Volume
- 10
- Issue
- S20
- Pages
- 26-34
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W2418563458
- Cited by
- 39
- References
- 8
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD. https://app.cochat.ai/papers/10.1017/s1092852900002418
- The paper
- Goodman, D. W., Ginsberg, L., Weisler, R. H., Cutler, A. J., & Hodgkins, P. (2005). An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD. CNS Spectrums. https://doi.org/10.1017/s1092852900002418
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.